Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Asthma, which is caused by inflammation of the airways, affects the sensitivity of nerve endings. Narcolepsy is a chronic sleep disorder that may be caused by autoimmunity. Recent studies have reported a positive association between narcolepsy and asthma. We aimed to examine the association between asthma and narcolepsy and determine the effects of therapeutic corticosteroid or bronchodilator use.
Materials And Methods: We conducted a nationwide population-based, nested case-control study using Taiwan's National Health Insurance Research Database (NHIRD) between 2000 and 2013. Subjects with narcolepsy (ICD-9-CM code 347) were enrolled, with 1:3 estimated propensity score-matched controls based on sex, age, and index year. The association between narcolepsy and asthma was assessed using multiple logistic regression analyses. The covariates included sex, age, monthly insurance premiums, geographical area of residence, urbanization level of residence, level of care, and presence of diseases related to immune response and central nervous system. The effects of corticosteroid and bronchodilator use were also analyzed.
Results: Overall, 2008 subjects were identified from the NHIRD (502 patients with narcolepsy and 1506 controls). The participants with narcolepsy had almost three times the level of previous asthma diagnosis than controls. Compared to those without asthma, patients with asthma had an adjusted odds ratio (OR) of 3.181 for narcolepsy comorbidity (95% confidence interval [CI]: 2.048-4.941, <0.001). The use of inhaled corticosteroids was associated with a lower risk of narcolepsy comorbidity, with an adjusted OR of 0.465 (95% CI, 0.250-0.634; <0.001), in patients with asthma when compared to those without treatment.
Conclusion: This study demonstrated a significantly higher level of previous asthma diagnosis in patients with narcolepsy. The use of inhaled corticosteroids was associated with a lower risk of narcolepsy comorbidity in asthma patients, compared to those without treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464343 | PMC |
| http://dx.doi.org/10.2147/NSS.S317746 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
REM Density, Leg Movements, and REM Sleep without Atonia: Differentiating Type 1 from Type 2 Narcolepsy Through Polysomnographic Analysis, a Preliminary Study.
Nat Sci Sleep
September 2025
Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, People's Republic of China.
Objective: This study aimed to identify distinct REM sleep characteristics that differentiate type 1 narcolepsy (NT1) from type 2 narcolepsy (NT2) using polysomnography (PSG), while acknowledging the need for future validation against other hypersomnia disorders.
Methods: A retrospective review included 31 patients with NT1, 21 patients with NT2, and 24 healthy participants. Each participant underwent overnight PSG and a subsequent multiple sleep latency test (MSLT) to assess REM sleep parameters including average REM density, neck myoclonus index, and leg movement index.
Sleep Paralysis: Pathogenesis, Clinical Manifestations, and Treatment Strategies.
J Integr Neurosci
August 2025
Neurological Institute of Jiangxi Province and Department of Neurology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, and Xiangya Hospital of Central South University at Jiangxi, 330038 Nanchang, Jiangxi, China.
Sleep paralysis, colloquially known as "ghost pressing" is a state of momentary bodily immobilization occurring either at the onset of sleep or upon awakening. It is characterized by atonia during rapid eye movement (REM) sleep that continues into wakefulness, causing patients to become temporarily unable to talk or move but possessing full consciousness and awareness of their surroundings. Sleep paralysis is listed in the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) as a parasomnia occurring during REM sleep that be classified as either isolated or narcolepsy-associated.
View Article and Find Full Text PDFDissolution of Once-Nightly Sodium Oxybate in Soft Foods and Alternative Liquid Reconstitution Vehicles.
Clin Ther
September 2025
Avadel Pharmaceuticals, Chesterfield, Missouri.
Purpose: Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of age or older with narcolepsy. ON-SXB contains both immediate-release and pH-dependent, controlled-release granules designed to be reconstituted in water and administered orally once at bedtime.
View Article and Find Full Text PDFPrevalence and Factors Associated with Rapid Eye Movement-Related Obstructive Sleep Apnea in Patients with Narcolepsy.
Nat Sci Sleep
August 2025
The University Sleep Disorders Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Purpose: Data on the prevalence and correlates of rapid eye movement (REM)-related obstructive sleep apnea (REM-OSA) in narcolepsy remains limited. This study aimed to assess the prevalence and independent associated factors with OSA and REM-OSA in patients with narcolepsy, and to compare the distribution of REM-OSA between patients with narcolepsy and matched controls without narcolepsy.
Patients And Methods: This retrospective study of a prospectively collected cohort included 190 adult patients with narcolepsy (narcolepsy type 1 [NT1] = 119, narcolepsy type 2 [NT2] = 71) who underwent polysomnography and multiple sleep latency test at the University Sleep Disorders Center, King Saud University Medical City, between January 2007 and February 2022.
A comprehensive study on drug-related Raynaud's phenomenon based on the FDA adverse event reporting system.
Sci Rep
September 2025
College of Rehabilitation Medicine, Fujian University of Chinese Medicine, Fuzhou, 350122, China.
Raynaud's phenomenon (RP) is often an overlooked adverse event, mainly secondary RP, where drug induction or exacerbation is a controllable and preventable factor. This study aimed to systematically evaluate the association between drugs and RP using the FDA adverse event reporting system (FAERS) database. Utilizing disproportionality analysis, we quantified the risk of RP-associated drugs based on large-scale FAERS case data.
View Article and Find Full Text PDF